Introduction
The risk for developing coronary heart disease is closely related to the serum total cholesterol or LDL cholesterol level, as well as to other factors. Accordingly, approaches to reduce the (LDL) cholesterol level may be expected to be effective in the prevention and treatment of coronary heart disease [1, 2] . Recent angiographic studies with various interventions and large intervention trials with HMG coenzyme A reductase inhibitors (simvastatin, pravastatin, lovastatin; 'statins') have confirmed that such lipid lowering therapy is effective in reducing the rates of death, myocardial infarction and subsequent revascularization procedures, in patients with (4S, CARE and LIPID) and subjects without (WOSCOPS, AFCAPS) known coronary heart disease [3] [4] [5] [6] [7] . While the treatment effects are large in relative terms, with an average reduction in myocardial infarction free survival of between 24% and 31%, they are small in absolute terms. Sizeable numbers of patients were treated for relatively long periods before a statistically significant reduction in hard end-points could be demonstrated: the annual risk reductions in myocardial infarction free survival varied between two to less than one per 100 patients treated. When large groups of people are treated for long periods of time, possibly life-long, the costs of such treatment are considerable. Therefore, the question arises in whom is treatment with statins warranted. In the Netherlands, this question was addressed by a committee of the CBO (National Organisation for Quality Improvement in Health care), an organization specializing in developing treatment guidelines. The CBO consensus committee decided to base its guidelines not only on considerations about effectiveness but also on costs-effectiveness, taking the position that groups of subjects, in whom the cost effectiveness of lipid lowering therapy is similar, should be managed similarly, with or without statins.
Before, during and after the consensus development, a number of publications have appeared which address the same subject [8] [9] [10] [11] [12] [13] [14] [15] [16] . The analysis presented here differs from previous publications in the sense that a general model was developed, on the understanding that treatment of patients with coronary heart disease (secondary prevention) and subjects without known coronary heart disease (primary prevention) should be considered as a continuum, with the risk for future events in a given patient and the expected treatment benefit as the crucial variables. Accordingly, the model was used to identify groups of subjects in whom treatment with statins was similarly cost-effective.
Methods
Since there was a dearth of experimental data from the Netherlands a modelling approach was followed combining Dutch unit cost data with data from the five clinical studies available: the Scandinavian Simvastatin Survival Study (4S), the CARE study, LIPID, the WO-SCOPS study and the AFCAPS study [3] [4] [5] [6] [7] . First, all trials were analysed separately. Second, a more general model was developed combining the results from the three studies.
The clinical data
The 4S study was the first major randomized clinical trial to prove the efficacy of a statin in reducing the death rate [3] . The study included 4444 patients from Scandinavia, aged between 35 and 70 with known coronary heart disease and relatively high cholesterol levels. Mortality decreased by 29% from 0·115 to 0·082 at 5 years, and the number of myocardial infarctions decreased by 35%. The CARE study included patients after a myocardial infarction with 'average cholesterol levels' [4] . The study included 4159 patients (mostly men) and the average duration of follow-up was 5 years.
The combined end-point of myocardial infarction/ cardiovascular death decreased by 19%, from 0·143 to 0·115. In LIPID, 9014 patients were included, with a history of myocardial infarction or unstable angina. At 6 years follow-up, cardiovascular mortality was reduced by 24% from 0·083 to 0·064. Total mortality decreased by 22% from 0·141 to 0·110.
While 4S, CARE and LIPID can be labelled as 'secondary-prevention' studies, one might label WOSCOPS and AFCAPS as 'primary prevention' studies [5] . WOSCOPS included subjects without a known history of heart disease, they had on average high cholesterol levels and most individuals were at a relatively high risk of developing coronary heart disease. The study was limited to males (6595) and the average follow-up period was 4·9 years. The combined end-point of myocardial infarction/cardiovascular death decreased by 33%, from 0·074 to 0·049. AFCAPS-TexCAPS included men between 45 and 73 years and women between 55 and 73 years. At a mean follow-up of 4·8 years, mortality was not affected by statin therapy. Nevertheless development of sudden cardiac death, myocardial infarction or hospitalization for unstable angina was reduced by 42%, from 0·055 to 0·032.
The model
The primary analyses regarding the trials were carried out in simple spreadsheet programs that combine life tables with probabilities of events, including death, fatal stroke, non-fatal stroke, fatal myocardial infarction, non-fatal myocardial infarction, PTCA and CABG. Table 1 presents the numbers of events which were used. It should be noted that the WOSCOPS study did not report separate figures for PTCA and CABG. It was assumed that both interventions were evenly distributed and evenly decreased (which is between CARE, LIPID and 4S). Additionally, the 4S data were used to estimate the distribution of fatal and non-fatal strokes for WOSCOPS and CARE, as these too were not reported. The data missing from AFCAPS/TexCAPS have been estimated using the observations from WOSCOPS.
With respect to the distribution of events in time, piecewise exponential distributions were assumed with an increase in cardiovascular event rates of 5% per year. First, the parameter of this distribution was estimated for the placebo group, such that the number of events predicted by the model equalled the observed number in the trial. Second, we used the fact that the published graphs concerning survival and event-free survival indicate that differences only occur after about 6 months in WOSCOPS, after about 1 year in 4S and after about 2 years in CARE. So, for the statin group, we assumed that during these first periods the event probabilities would be equal to the placebo group and that the curves would start to separate after those periods. Again, piecewise exponential distribution was assumed and (given the parameter for the first period based on the placebo group) the parameter of this distribution was estimated such that the number of events simulated by the model was identical to the observed number of events.
After analysing the balance between costs and effects on a 5-year time horizon, costs and effects were extrapolated over longer time horizons. In these calculations, the continued effect of statin therapy was assumed, including a continued reduction of deaths, myocardial infarctions, coronary interventions as well as strokes, as the results in Table 1 strongly suggest that statin therapy is also effective in preventing strokes. Additionally, an increase in the risk of dying from other causes was taken into account, which -on the basis of Dutch life tables -was estimated to increase by 10% per year, from 0·3% at the age of 50 to 2% at the age of 70.
Costs
Total costs with and without statin therapy were obtained by considering the costs of medication and by multiplying the various events -as considered in the model -with unit costs per event. The unit costs per event were restricted to direct medical costs, estimated on the basis of different studies in the Netherlands [17] . The costs of non-fatal and fatal myocardial infarction and the costs of death were derived from the economic evaluation of the 4S study carried out by Jö nsson et al. [8, 10] . The latter data -collected during the trial -show that the number of hospitalizations related to a myocardial infarction are about 1·625 times the number of infarctions. Therefore the Dutch estimate of the costs of a myocardial infarction associated hospitalization (based on data from the REGRESS study) [18] were multiplied with this factor. The costs of death were estimated such that there were no differences left between the current and the 4S analysis, taking account of the numbers of myocardial infarctions, PTCAs or CABGs. As such, one may interpret the costs of death as a proxy of costs that have not been included due to a lack of data. Table 2 presents the estimates of the costs per event or per year.
Effects
Lacking data about quality of life, effects were measured in life years and in 'event-free surviving years' including stroke and myocardial infarction as events. As no specific data were available about which events occurred in which patients, event-free survival was calculated by assuming independence between the various risks.
Cost effectiveness
Cost effectiveness was expressed in terms of the additional costs per additional life year gained. Furthermore, additional costs were calculated for each additional year gained without stroke or myocardial infarction. With respect to the trial results, estimates are presented after 5 years, after 10 years and for life-long Number of events, and event rates as observed in three trials with simvastatin and pravastatin. MI=myocardial infarction; DMI=definite MI; PMI=probable MI; FMI=fatal MI; NFMI=non-fatal MI; CABG=aorto coronary bypass surgery; PTCA=percutaneous transluminal coronary angioplasty; CHD=coronary heart disease. *Estimated figures, see text for explanation. The reported event rates are total stroke and total revascularization procedures (CABG+PTCA).
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treatment (25 years treatment). Cost effectiveness was calculated only for life-long treatment, assuming no differences in death from causes other than cardiovascular. In the calculations, it was assumed that patients would continue to take the drugs and that the additional benefits would persist. An alternative assumption might be that patients would stop treatment after 5 or after 10 years. This alternative is addressed in the sensitivity analysis. In the latter analysis, no specific effects were attributed to discontinuation of therapy, neither with respect to costs nor with respect to effects. Both costs and effects are discounted with a 5% discount rate.
Who to treat cost effectively?
To be able to answer the question whom to treat, the data from the various trials are brought together in such a way that interpolation and extrapolation are possible by way of a 'meta-model'. Here, an even simpler structure is followed than in the models presented above. The analysis is limited to coronary heart disease death, death from other causes, non-fatal myocardial infarction/ stroke, and PTCA/CABG. A constant relationship is assumed between the occurrence of coronary heart disease death, myocardial infarction and stroke and the need for revascularization, together with a constant risk reduction in those events. Under these assumptions, the balance between the costs and effects is completely determined by the patient's cardiovascular risk and his/her probability of dying from other causes. With this model a cost effectiveness ratio is calculated for each patient, given age, gender and risk profile. Assuming a threshold value for the costs per life year gained, it is then calculated what an individual's minimal risk should be to be under this threshold for each age and sex group. In these calculations a threshold of DFL 40 000 (Euro 18 151 or $18 000) was applied.
Sensitivity analysis
A univariate sensitivity analysis was carried out with respect to the various cost estimates and the estimates concerning effectiveness. An additional analyses assumed that instead of life-long treatment, patients stopped statin treatment after 5 or 10 years. The results would assume that the effectiveness of statin treatment decreases with age.
Results
The reported follow-up in the five trials analysed is approximately 5 years. At that moment in time, mean survival ranges from 4·75 to 4·94 years and mean survival without stroke or myocardial infarction ranges from 4·32 to 4·89 years ( Table 3 ). The survival benefit from statin therapy ranged from 0·01 year (CARE) to 0·05 year (4S), while no survival benefit was observed in AFCAPS, which included a relatively low risk population. Under the assumptions of the model, the survival benefit as well as the additional event-free survival from statin therapy, increased at longer follow-up. Additional costs per life year gained ranged from approximately Euro 6700 to Euro 51 400 and costs per event-free year (without stroke or myocardial infarction) ranged from approximately Euro 3600 to Euro 8600. It is evident that statin therapy is most effective and most cost effective in the patients who were included in the 4S study. The lowest event rate and the smallest benefit of statin therapy were observed in WOSCOPS and particularly AFCAPS. Part of the difference in costs between 4S and CARE and LIPID is explained by the relatively high number of CABG procedures (in comparison to PTCA) in 4S. The difference between the cost effectiveness of LIPID and CARE is explained by the high number of patients in the CARE study with very low cholesterol levels in whom little benefit was apparent (21%). When this subgroup is excluded from the analysis, the cost effectiveness ratio is approximately Euro 7500.
In spite of the differences, the studies show several remarkable similarities. After a period without any clinical effects, there is a significant reduction of about 35% in the incidence of cardiovascular deaths, myocardial infarctions, strokes and revascularizations. The costs of medication are about Euro 550 (taking account 0f subjects who stop medication) per year, the costs of dying about Euro 1100, the costs of myocardial infarction and/or stroke about Euro 8000 and the costs of revascularization about Euro 10 000. When we assume a constant ratio between cardiovascular death and myocardial infarction/stroke of 1:1.98 and a constant ratio between cardiovascular death and revascularization of 1:2.51 (the averages from the five trials) and when we assume that it takes on average 1 year before therapy becomes effective, we may express the cost effectiveness of statin therapy as a simple function of the risk for future events in a given patient. Figure 1 represents this function when cost effectiveness after 25 years is expressed as a function of the patients' 10-year risk for cardiovascular death, myocardial infarction or stroke. From Fig. 1 (Table 3) , when corrected for the costs of medication, which underlines the applicability of the meta-model. An arbitrary, derived level of cost effectiveness of a maximum of NLG 40 000 (Euro 18 151) per life year gained is achieved in subjects with a 10-year risk for cardiovascular death, stroke or myocardial infarction exceeding 20·2%. Similarly, a limit of NLG 30 000 (Euro 13 613) is achieved in subjects with a 10-year risk exceeding 25·2%. In the calculations underlying Fig. 1 , the average probability of dying from other causes was -based on the average from the three studies -estimated at 0·46% per year during the first 5 years. This probability will differ for various ages and for men and women and as a result so the cut-off points of 20·2% and 25·2% may also differ for various ages. By taking different probabilities of dying from other causes we may derive for each age and sex group a different cut-off point in terms of 10-year risk for cardiovascular death, stroke, or myocardial infarction, above which the cost effectiveness ratio is not below some threshold. The results, for men and women, using a threshold of NLG 40 000 (Euro 18 151) and of NLG 30 000 (Euro 13 613) per life year gained, are presented in Fig. 2 . At all ages, the cut-off level is higher the older the subject, since the elderly have a lower life expectancy and a greater Table 3 For survival as well as myocardial infarction/stroke-free survival, the mean survival is presented at 5 and 10 years, respectively, for life-long follow-up. 
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probability of dying from other causes, unaffected by statin therapy. Similarly, the cut-off level is lower for women than men because women have a longer life expectancy.
Sensitivity analysis
The model is characterized by a number of assumptions and estimates that are surrounded by uncertainties. In the main analysis, it was estimated that patients with a 10-year risk for cardiovascular death, stroke or myocardial infarction of more than 20·2% would reach a cost effectiveness ratio of under Euro 18 151 per life year gained. Table 4 presents the corresponding cut-off levels, when assuming a 25% increase in the subsequent estimates of costs and effectiveness. The results are mainly driven by the costs of medication and the assumption about effectiveness, and appear to be relatively insensitive to changes in the costs per event.
The baseline analysis calculated costs and effects in terms of life-long treatment and persisting effectiveness. Another approach would have been to assume that patients would stop treatment after 5 years and that treatment effects would stop thereafter (implying no additional differences in the conditional survival probabilities after 5 years). This would increase the cost effectiveness ratios with, respectively, Euro 1758 (4S), Euro 2195 (LIPID), Euro 2217 (CARE), Euro 3790 (WOSCOPS) and Euro 7762.
Thus a shorter treatment duration implies thatgiven some threshold for acceptability -patients require a higher risk before a similar cost effectiveness is achieved. This is illustrated in Fig. 3 where the DFL 40 000 threshold curve is compared for 25-year treatment with that assuming 5-year treatment.
Effect of age
Finally, an analysis was made, on the assumption that the effectiveness of statin therapy decreases with age. On the basis of Law's meta-analysis it was postulated that the effectiveness of statin therapy, being about 35% in the age group 55-60, decreases from 59% for the age group between 40 and 45 to about 19% in the age group above 85 [19] . As may be expected from the univariate sensitivity analysis, this approach results in a lower risk level compatible with a cost effectiveness of Euro 18 000 at younger age, (11% risk below the age of 30) and a higher threshold in older age groups (45% risk over the age of 80, Fig. 4 ).
Discussion
Lipid lowering therapy is prescribed in patients with coronary artery disease, and in healthy subjects at increased risk for such disease. Once initiated, this therapy is usually continued for many years, perhaps life-long. However, it should be appreciated that the clinical trials documenting the benefits of statin therapy were mostly restricted to male subjects, at middle age, who were treated for approximately 5 years. Yet the results are often extrapolated and treatment is prescribed to others, including elderly subjects. As long as specific data on elderly subjects or during longer follow-up are lacking, the model presented in this paper may help to estimate the expected effectiveness of statin therapy in different groups in whom such therapy is considered. The effectiveness of lipid lowering therapy, and more specifically therapy with HMG coenzyme A reductase inhibitors (statins), in delaying further development of coronary disease [18, 20, 21] and in reducing, or rather delaying the development of coronary events has been well established in a series of clinical trials in different populations [3] [4] [5] [6] [7] . In particular, the risk of cardiovascular death as well as the risk for myocardial infarction is reduced by 9% to 31% while the risk for stroke appears similarly reduced. In low risk populations only a reduction in non-fatal coronary events was observed, without survival benefit at 5 years follow-up [6] .
Effectiveness
The effectiveness of treatment with simvastatin, pravastatin or lovastatin is similar, in relative risk reduction, among the trials and among different subgroups within the trials. Therefore, it is evident that the absolute benefit, expressed as life years gained, or event-free life years gained, will be greater, and cost-effectiveness better (lower costs) in subjects at greater risk for cardiovascular events. Lipid lowering therapy does delay development of coronary heart disease, but not development of other diseases. Thus, the effectiveness will be lower, and cost effectiveness higher (worse) in subjects with a reduced life expectancy and a greater likelihood of dying from other causes, such as patients with severe heart failure and elderly persons. In all studies, a lag-time was observed before any clinical benefit of statin therapy became apparent, ranging from 6 months to 2 years. Accordingly, the prescription of statins to the elderly should be reserved for those at high risk for the development or progression of coronary disease, who do have sufficient life expectancy to benefit. A restricted use of statins in the elderly is particularly appropriate if the meta analysis is accepted, which indicates a lesser benefit of cholesterol lowering in elderly compared to younger people (Fig. 4) . This concept is supported by observations in the 'oldest old' with an inverse relationship between cholesterol and mortality risk [22] . The distinction between primary and secondary prevention is artificial, since coronary disease develops gradually with a prolonged subclinical phase in many individuals [23] . The model presented in this paper uses a unifying concept of risk assessment and risk reduction. According to this approach, statin therapy will be more appropriate in a 60-year-old female with a family history of coronary heart disease, diabetes and a total cholesterol of 7 mmol . l 1 (primary prevention), than in a 50-year-old male after PTCA and stent implantation for single vessel coronary disease with a total cholesterol of 6 mmol . l 1 , without additional risk factors after stopping smoking (secondary prevention). The 10-year risk for death, stroke or myocardial infarction in the former is approximately 26% [24] and in the latter patient only approximately 17% [25] .
Cost effectiveness
Cost effectiveness analysis has been used to argue in favour (or against) introduction of new treatment modalities which were judged by some to be too expensive (and also to compare different treatment 
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options for the same patient for example stent implantation or bypass surgery for patients with multivessel coronary disease) [26] . In the present analysis, costeffectiveness was used as a method of providing equal care (including statin therapy) to people with a similar risk for future events, whether as 'primary' or as 'secondary' prevention. The Netherlands Consensus Committee judged, quite arbitrarily, that statin therapy is warranted in most patients with known cardiovascular disease who meet the enrolment criteria of the 4S, CARE and LIPID studies, as well as in otherwise healthy subjects with a similar high risk for death, myocardial infarction or stroke.
Primary prevention will be less cost effective in many cases. In fact, society or the government as its representative, should specify which level of cost effectiveness or total costs can be accepted. The presented model may help to guide decision making in individual subjects, given a derived level of cost-effectiveness for prevention of coronary heart disease.
The cost-effectiveness ratio of treatment in 4S, CARE and LIPID subjects (excluding the low cholesterol subgroup in CARE) is Euro 10 000 or less. For other prevention programmes cost-effectiveness ratios of Euro 10 000 to Euro 14 000 (DFL 30 000) have been accepted in the Netherlands. Even if a generous threshold of Euro 18 000 is selected for lipid-lowering therapy, treatment in the WOSCOPS or AFCAPS/TexCAPS populations, even with relatively high cholesterol levels, may not be acceptable from a society/economic point of view. Primary prevention, according to a criterion of costs less than Euro 18 000 per life year gained, will be appropriate only in patients who combine multiple risk factors such as diabetes, smoking, and hypertension (see Appendix). In other words, society may not be prepared to pay an annual amount of approximately Euro 550 for a decrease in an individual's annual risk from about 2% to about 1·4% [5] . Whether this is reasonable or not, can always be debated. Within such debates, one might wonder what a person would do, when given Euro 500 per year and confronted with the choice of spending it on statin therapy or adding it to his freely disposable income.
Total costs of lipid lowering therapy
Apart from considerations about cost effectiveness, total costs for the community should be taken into account before accepting a therapy. The number of subjects to be treated, and the resulting total costs should be taken into account in such decisions. It is likely that a more expensive treatment (high cost-effectiveness ratio) will be accepted if the use is restricted, for example, heart transplantation, while lower cost-effectiveness ratios will be applied for preventive therapy, which might be prescribed to a sizeable proportion of the population.
This applies particularly in 'preventive therapy' with drugs such as statins, which may be applied to a large proportion of the population. The costs of such therapy are approximately Euro 550 per patient per year. In the Netherlands in 1997 approximately Euro 100 million was spent on lipid-lowering drugs. This corresponds to 3·64% of the total medication expenses and 0·36% of the health care budget, or Euro 6 per inhabitant, children and elderly included! A major increase in these expenses is not acceptable within the constraints of the health care budget. Accordingly, it may be debated whether statin therapy should be prescribed to low-risk individuals if 100 of such would have to be treated for almost 5 years each to avoid one myocardial infarction, without an apparent effect on mortality (AFCAPS) [6] . In fact, we estimated that the strict application of guidelines, in considering statin therapy in all subjects with a 10-year risk for (new) coronary events exceeding the age-dependent thresholds in Fig. 4(a) , would result in treating 18 000 to 34 000 per million inhabitants. The associated costs would amount to Euro 9 000 000, to Euro 26 000 000, depending on the agents and dosages used in clinical practice. This might almost double the 1997 costs for statins in the Netherlands.
Model parameters, sensitivity analysis, costs of medication
The proposed model uses several assumptions, which may be questioned. These include factors which were Figure 4 Relationship between age, gender and the risk in a patient for whom the costs per life year gained are exactly DFL 40 000 (Euro 18 000), respectively DFL 30 000 (Euro 13 500). The effectiveness of lipid lowering therapy is assumed to decrease with age [19] . estimated from the trials (Table 1) such as: the number of events and their distribution over time, the delay after onset of treatment at which the benefit of therapy becomes apparent and the size of event reduction by statin therapy. Furthermore, the outcome of the model depends on the estimation of the risk of dying from other causes, and on the assigned direct costs of different events. Yet, the sensitivity analysis implies that the outcome, i.e. cost-effectiveness, is mainly dependent on the cost of therapy and the relative risk reduction. This implies that the answer to the question who to treat depends largely on the price of statins. For example, when considering a price of Euro 100 per year, treatment would be acceptable and would be indicated in everybody for whom the therapy can be called effective, including the low risk AFCAPS population [6] . In that case other arguments than cost effectiveness may enter the considerations, such as the burden of taking the medication and the social costs associated with medicalization. It should also be appreciated that the trials summarized in Table 1 show additional benefits apart from improved survival. In particular, the incidence of myocardial infarction and stroke was reduced by statin therapy, as well as the need for revascularization procedures. The calculated cost effectiveness would be lower (more cost-effective) if the costs per event-free life year were used (Table 3) . While this might give a more favourable impression (favouring wider use of statins), this would not change the estimates of total health care costs involved (see above), or the comparison of costeffectiveness of so-called 'primary' and 'secondary' prevention. Furthermore, 'costs per life year saved' were calculated for many other cardiovascular therapies, which facilitates comparison of the relative merits in terms of cost effectiveness.
The presented analysis focused on the direct costs of health care, and did not include indirect costs related to work or unemployment, rehabilitation, or costs of future health care requirements. Again, this is comparable to many other studies of cost effectiveness of cardiovascular therapy. Furthermore, it should be appreciated that any measure which prolongs life will significantly increase health care costs in the future, even if it is immediately cost saving, such as stopping smoking [27] .
Conclusion
The model described in this paper compares the effectiveness and cost-effectiveness of cholesterol lowering therapy among a large group of subjects without and patients with coronary heart disease. Accordingly, the model may guide physicians to prescribe relatively expensive drugs in a systematic manner to subjects with similar expected benefits (see Appendix). In this setting it should be appreciated that medical treatments to reduce cholesterol are only one of many ways of reducing cardiovascular risk. To quit smoking may be a more effective way and one might wonder whether society should allocate money to those who are at high risk due to their own behaviour. This may be considered one of many examples where a simple application of the cost effectiveness toolkit may not be appropriate. The economic balance is just one argument in medical decision making and many other considerations need to be taken into account before decisions to treat or not to treat can be taken. 
Treatment of coronary artery disease with lipid lowering therapy
A series of angiographic trials as well as the results of three larger trials in patients with coronary artery disease have shown retardation of the progression of coronary artery disease, and improved outcome in patients receiving lipid lowering therapy, particularly statins. The results were remarkably consistent. The follow-up period was approximately 5 years, although in practice treatment initiated will be continued for considerably longer periods. In fact, it may be expected that the greatest benefit will be achieved with long-term lipid lowering therapy, assuming that the effects observed during the first 5 years will be sustained. In particular the committee does not recommend initiation of lipid lowering therapy in males over the age of 70 or in females over the age of 75, since the risk associated with high cholesterol concentrations is less apparent at advanced age, and since patients at elderly age were not included in previous trials.
Trials addressing the potential benefit of lipid lowering therapy in elderly patients are currently ongoing.
Prevention of coronary artery disease by lipid lowering therapy in subjects without apparent coronary artery disease but at increased risk
Lipid lowering therapy should be considered if the risk in such subjects is similar to the risk for new events in patients with known coronary artery disease. In CARE, LIPID and 4S the risk for new events was 36%, 36% and 48% in 10 years. A lower threshold might be chosen for younger subjects, and a higher threshold for the elderly. The risk for development of coronary artery disease may be estimated from the total cholesterol / HDL cholesterol concentration ratio in combination with other factors including age, gender, diabetes, smoking and hypertension. The enclosed colour chart is derived from Framingham data and indicates the 10 year risk for development for coronary artery disease. Lipid lowering therapy is not recommended in the yellow area of the table. Treatment should be considered in the red area, while a border zone is indicated in orange. Subjects in the border zone are candidates for lipid lowering therapy if other risk factors are present, not specifically used in the table, such as a family history of early coronary artery disease.
Numbers of candidates for statin therapy in the population, and total costs
From registry data in the Netherlands the committee estimated the number of patients per million inhabitants which might be candidates for lipid lowering therapy with statins. This number ranges from 18 000 (low estimate) to 34 000 (high estimate) per million inhabitants. The costs of such treatment would amount to about Euro 9 000 000 to 26 000 000 per million inhabitants per year. Members of the Netherlands Consensus Committee
